公开(公告)号：US20230093109A1

公开(公告)日：2023-03-23

申请号：US17990332

申请日：2022-11-18

Applicant: BioXcel Therapeutics, Inc.

Inventor： Krishnan NANDABALAN ,  Frank YOCCA ,  Sameer SHARMA ,  Harsh NEGI ,  Deepa SAINI

IPC: A61K31/4174 ,  A61K9/00 ,  A61K9/20 ,  A61K47/10 ,  A61K45/06

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

公开(公告)号：US20220031663A1

公开(公告)日：2022-02-03

申请号：US17496470

申请日：2021-10-07

Applicant: BioXcel Therapeutics, Inc.

Inventor： Krishnan NANDABALAN ,  Frank YOCCA ,  Sameer SHARMA

IPC: A61K31/4174 ,  A61K9/00 ,  A61K9/20 ,  A61K45/06 ,  A61K47/10

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

公开(公告)号：US20240252471A1

公开(公告)日：2024-08-01

申请号：US18526686

申请日：2023-12-01

Applicant: BioXcel Therapeutics, Inc.

Inventor： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC: A61K31/4174 ,  A61K9/00 ,  A61K47/38 ,  A61P25/18 ,  A61P25/20

CPC classification number: A61K31/4174 ,  A61K9/006 ,  A61K47/38 ,  A61P25/18 ,  A61P25/20

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US20240252470A1

公开(公告)日：2024-08-01

申请号：US18436589

申请日：2024-02-08

Applicant: BioXcel Therapeutics, Inc.

Inventor： Krishnan NANDABALAN ,  Frank YOCCA ,  Sameer SHARMA ,  Harsh NEGI ,  Deepa SAINI

IPC: A61K31/4174 ,  A61K9/00 ,  A61K9/20 ,  A61K45/06 ,  A61K47/10

CPC classification number: A61K31/4174 ,  A61K9/006 ,  A61K9/2027 ,  A61K45/06 ,  A61K47/10

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses die sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

公开(公告)号：US20230218580A1

公开(公告)日：2023-07-13

申请号：US18124943

申请日：2023-03-22

Applicant: BioXcel Therapeutics, Inc.

Inventor： Krishnan NANDABALAN ,  Frank YOCCA ,  Sameer SHARMA ,  Harsh NEGI ,  Deepa SAINI

IPC: A61K31/4174 ,  A61K9/00 ,  A61K9/20 ,  A61K45/06 ,  A61K47/10

CPC classification number: A61K31/4174 ,  A61K9/006 ,  A61K9/2027 ,  A61K45/06 ,  A61K47/10

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

公开(公告)号：US20240024288A1

公开(公告)日：2024-01-25

申请号：US17628021

申请日：2020-07-17

Applicant: BioXcel Therapeutics, Inc. ,  ARx, LLC

Inventor： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Scott David BARNHART ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC: A61K31/4174 ,  A61P25/18 ,  A61K9/00 ,  A61P25/20 ,  A61P25/36

CPC classification number: A61K31/4174 ,  A61P25/18 ,  A61K9/006 ,  A61P25/20 ,  A61P25/36

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US20230414572A1

公开(公告)日：2023-12-28

申请号：US18242236

申请日：2023-09-05

Applicant: BioXcel Therapeutics, Inc.

Inventor： Harsh NEGI ,  Deepa SAINI ,  Sameer SHARMA ,  Krishnan NANDABALAN ,  Frank YOCCA

IPC: A61K31/4174 ,  A61K9/00

CPC classification number: A61K31/4174 ,  A61K9/006 ,  A61K9/0056 ,  A61K9/2018

Abstract: There is provided a composition suitable for oral transmucosal administration (sublingual) comprising dexmedetomidine. The composition is useful for the treatment of sleep disorders such as insomnia and capable of providing sleep on demand. The composition comprises an effective amount of dexmedetomidine or pharmaceutically acceptable salts thereof, solvates thereof, or derivatives thereof, formulated for delivery of dexmedetomidine across a subject's oral mucosa.

公开(公告)号：US20230338339A1

公开(公告)日：2023-10-26

申请号：US18216890

申请日：2023-06-30

Applicant: BioXcel Therapeutics, Inc.

Inventor： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC: A61K31/4174 ,  A61P25/18 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/70 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44

CPC classification number: A61K31/4174 ,  A61P25/18 ,  A61K9/006 ,  A61K9/06 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/7007 ,  A61K9/7015 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US20230118091A1

公开(公告)日：2023-04-20

申请号：US17993422

申请日：2022-11-23

Applicant: BioXcel Therapeutics, Inc. ,  ARx, LLC

Inventor： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Scott David BARNHART ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC: A61K31/4174 ,  A61K9/00 ,  A61K9/70 ,  A61P25/18 ,  A61K47/38 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K47/34 ,  A61K9/20 ,  A61K9/06

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US20200000717A1

公开(公告)日：2020-01-02

申请号：US16453679

申请日：2019-06-26

Applicant: BioXcel Therapeutics, Inc. ,  ARx, LLC

Inventor： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Scott David BARNHART

IPC: A61K9/00 ,  A61K31/4174 ,  A61K9/70 ,  A61K47/38 ,  A61K47/34 ,  A61P25/22

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.